Literature DB >> 21080803

Therapy and prophylaxis of brain metastases.

Yvonne Kienast1, Frank Winkler.   

Abstract

Metastases of various tumors to the brain account for the majority of brain cancers, and are associated with a poor prognosis. The most common primary sites are lung, breast, skin, kidney and colon; 10-40% of cancer patients develop brain metastases during the course of the disease. The incidence of brain metastasis appears to be rising; reasons may include better therapies for the systemic disease with longer survival of cancer patients but lower efficiency against brain metastases. In this article, we will discuss the conventional treatment with surgery, radiosurgery, radiotherapy and chemotherapy, but also new directions in the management of solid brain metastases. While general therapeutic nihilism should be avoided, it is important to recognize that the number of brain metastases, the extent of the systemic disease and also the tumor type have to be taken into account when choosing individual treatment regimens. Finally, special emphasis will be put on established and future approaches to prevent the disease. We thus aim to provide a framework for treating patients with different presentations of brain metastases, and to highlight important avenues for research.

Entities:  

Mesh:

Year:  2010        PMID: 21080803     DOI: 10.1586/era.10.165

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  14 in total

Review 1.  Management of brain metastasis: past lessons, modern management, and future considerations.

Authors:  Eugene Koay; Erik P Sulman
Journal:  Curr Oncol Rep       Date:  2012-02       Impact factor: 5.075

2.  Expression profiling of angiogenesis-related genes in brain metastases of lung cancer and melanoma.

Authors:  Aysegül Ilhan-Mutlu; Christian Siehs; Anna Sophie Berghoff; Gerda Ricken; Georg Widhalm; Ludwig Wagner; Matthias Preusser
Journal:  Tumour Biol       Date:  2015-08-16

Review 3.  The brain metastatic niche.

Authors:  Frank Winkler
Journal:  J Mol Med (Berl)       Date:  2015-11       Impact factor: 4.599

4.  Opposing effects of pigment epithelium-derived factor on breast cancer cell versus neuronal survival: implication for brain metastasis and metastasis-induced brain damage.

Authors:  Daniel P Fitzgerald; Preeti Subramanian; Monika Deshpande; Christian Graves; Ira Gordon; Yongzhen Qian; Yeva Snitkovsky; David J Liewehr; Seth M Steinberg; José D Paltán-Ortiz; Mary M Herman; Kevin Camphausen; Diane Palmieri; S Patricia Becerra; Patricia S Steeg
Journal:  Cancer Res       Date:  2012-01-01       Impact factor: 12.701

5.  Maintaining unperturbed cerebral blood flow is key in the study of brain metastasis and its interactions with stress and inflammatory responses.

Authors:  Amit Benbenishty; Niva Segev-Amzaleg; Lee Shaashua; Rivka Melamed; Shamgar Ben-Eliyahu; Pablo Blinder
Journal:  Brain Behav Immun       Date:  2017-02-20       Impact factor: 7.217

Review 6.  The role of cancer stem cells and miRNAs in defining the complexities of brain metastasis.

Authors:  Ashhar S Ali; Aamir Ahmad; Shadan Ali; Bin Bao; Philip A Philip; Fazlul H Sarkar
Journal:  J Cell Physiol       Date:  2013-01       Impact factor: 6.384

7.  Characterization of the inflammatory response to solid cancer metastases in the human brain.

Authors:  Anna Sophie Berghoff; Hans Lassmann; Matthias Preusser; Romana Höftberger
Journal:  Clin Exp Metastasis       Date:  2012-07-01       Impact factor: 5.150

8.  Role of the endothelin axis in astrocyte- and endothelial cell-mediated chemoprotection of cancer cells.

Authors:  Seung Wook Kim; Hyun Jin Choi; Ho-Jeong Lee; Junqin He; Qiuyu Wu; Robert R Langley; Isaiah J Fidler; Sun-Jin Kim
Journal:  Neuro Oncol       Date:  2014-07-09       Impact factor: 12.300

9.  β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma.

Authors:  W Shawn Carbonell; Michael DeLay; Arman Jahangiri; Catherine C Park; Manish K Aghi
Journal:  Cancer Res       Date:  2013-05-03       Impact factor: 12.701

10.  Macrolide analog F806 suppresses esophageal squamous cell carcinoma (ESCC) by blocking β1 integrin activation.

Authors:  Li-Yan Li; Hong Jiang; Yang-Min Xie; Lian-Di Liao; Hui-Hui Cao; Xiu-E Xu; Bo Chen; Fa-Min Zeng; Ying-Li Zhang; Ze-Peng Du; Hong Chen; Wei Huang; Wei Jia; Wei Zheng; Jian-Jun Xie; En-Min Li; Li-Yan Xu
Journal:  Oncotarget       Date:  2015-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.